{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:27Z","timestamp":1793317587084,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00198-017-3919-1","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T01:40:56Z","timestamp":1485826856000},"page":"1723-1732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":215,"title":["Observations following discontinuation of long-term denosumab therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"M. R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"3919_CR1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney RJ, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335","journal-title":"J Bone Miner Res"},{"key":"3919_CR2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2014where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"3919_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/GME.0b013e31829ef343","volume":"21","author":"DL Diab","year":"2014","unstructured":"Diab DL, Watts NB (2014) Use of drug holidays in women taking bisphosphonates. Menopause 21:195\u2013197","journal-title":"Menopause"},{"key":"3919_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"key":"3919_CR5","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","volume":"291","author":"E Banks","year":"2004","unstructured":"Banks E, Beral V, Reeves G, Balkwill A, Barnes I, Million Women Study Collaborators (2004) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291:2212\u20132220","journal-title":"JAMA"},{"key":"3919_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","volume":"10","author":"E Barrett-Connor","year":"2003","unstructured":"Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA, Berger ML, Santora AC, Sherwood LM (2003) Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 10:412\u2013419","journal-title":"Menopause"},{"key":"3919_CR7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.AOG.0000114986.14806.37","volume":"103","author":"J Yates","year":"2004","unstructured":"Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES (2004) Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 103:440\u2013446","journal-title":"Obstet Gynecol"},{"key":"3919_CR8","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","volume":"299","author":"G Heiss","year":"2008","unstructured":"Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, WHI Investigators (2008) Health risks and benefits 3\u00a0years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036\u20131045","journal-title":"JAMA"},{"key":"3919_CR9","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024\u20132030","journal-title":"Arch Intern Med"},{"key":"3919_CR10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507\u20131513","journal-title":"J Bone Miner Res"},{"key":"3919_CR11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Freedom Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"3919_CR12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E, Krieg MA, Man Z, Mellstr\u00f6m D, Radominski SC, Reginster JY, Resch H, Rom\u00e1n Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694\u2013701","journal-title":"J Bone Miner Res"},{"key":"3919_CR13","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"key":"3919_CR14","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773\u20132783","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"3919_CR15","first-page":"S471","volume":"30","author":"HG Bone","year":"2015","unstructured":"Bone HG, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Dakin P, Wagman RB, Papapoulos S (2015) Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension Trial. J Bone Miner Res (ASBMR Annual Meeting Abstracts) 30(Suppl 1):S471","journal-title":"J Bone Miner Res (ASBMR Annual Meeting Abstracts)"},{"key":"3919_CR16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"3919_CR17","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832\u20131841","journal-title":"J Bone Miner Res"},{"key":"3919_CR18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, AMG 162 Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"3919_CR19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402","journal-title":"J Clin Endocrinol Metab"},{"key":"3919_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227\u2013235","journal-title":"Osteoporos Int"},{"key":"3919_CR21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875\u2013883","journal-title":"Ann Intern Med"},{"key":"3919_CR22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","volume":"11","author":"RD Wasnich","year":"2004","unstructured":"Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC, Early Postmenopausal Intervention Cohort Study Group (2004) Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11:622\u2013630","journal-title":"Menopause"},{"key":"3919_CR23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"3919_CR24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242\u2013251","journal-title":"J Bone Miner Res"},{"key":"3919_CR25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","volume":"163","author":"BH Ascott-Evans","year":"2003","unstructured":"Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME (2003) Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med 163:789\u2013794","journal-title":"Arch Intern Med"},{"key":"3919_CR26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, PaTH Study Investigators (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"3919_CR27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326","journal-title":"Osteoporos Int"},{"key":"3919_CR28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","volume":"27","author":"S Boonen","year":"2012","unstructured":"Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2014a perspective. J Bone Miner Res 27:963\u2013974","journal-title":"J Bone Miner Res"},{"key":"3919_CR29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1359\/jbmr.091006","volume":"25","author":"KK Ivaska","year":"2010","unstructured":"Ivaska KK, Gerdhem P, V\u00e4\u00e4n\u00e4nen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9\u00a0years. J Bone Miner Res 25:393\u2013403","journal-title":"J Bone Miner Res"},{"key":"3919_CR30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, T\u00f6rring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6\u00a0Months (FREEDOM) trial. J Bone Miner Res 28:746\u2013752","journal-title":"J Bone Miner Res"},{"issue":"5\u20136 Suppl 2","key":"3919_CR31","first-page":"S91","volume":"9","author":"BR Egerdie","year":"2015","unstructured":"Egerdie BR, Tammela T, Sieber P, Lamy O, Ke C, Warner D (2015) Denosumab treatment for bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer: 5-year safety follow-up. Can Urol Assoc J (CUA Annual Meeting Abstracts) 9(5\u20136 Suppl 2):S91","journal-title":"Can Urol Assoc J (CUA Annual Meeting Abstracts)"},{"key":"3919_CR32","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929\u20131930","journal-title":"Osteoporos Int"},{"key":"3919_CR33","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925","journal-title":"Osteoporos Int"},{"key":"3919_CR34","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921","journal-title":"Osteoporos Int"},{"key":"3919_CR35","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Postmenopausal osteoporosis. N Engl J Med 374:2096\u20132097","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-3919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-3919-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-3919-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T23:39:24Z","timestamp":1568763564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-3919-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-3919-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}